AARD - Total Utang marang Modal Aardvark Pharma

Logo perusahaan publik Aardvark Therapeutics Inc (AARD)

The confirmed price history on the Aardvark Therapeutics Inc (AARD) total debt-to-equity chart stands at 0.01, driven by the development of unique weight-loss treatments via the stimulation of bitter taste receptors within a secure US legal framework. The business relies on the humanitarian status of its research, which eliminates trade risks. Growth is accelerating through partnerships with scientific centers that optimize the validation of new molecules.

AARD: Total Utang marang Modal Aardvark Therapeutics 14.02.2025 - 01.11.2026

Rincian analitis perusahaan Aardvark Therapeutics Inc

- rega lan prakiraan konsensus rega:
Bagan rega Aardvark Therapeutics|AARD - Bagan tingkat prakiraan
- statistik kapitalisasi pasar:
Kapitalisasi pasar Aardvark Therapeutics|AARD - Nilai Dipunlarasaken Utang lan Kas
- indikator kapitalisasi buku:
Nilai Buku saben Saham Aardvark Therapeutics|AARD - Kapitalisasi Buku|Rasio Nilai Pasar marang Nilai Buku aardvarktherapeutics.com|AARD - Nilai Agregat Aset
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas Aardvark Therapeutics Inc|AARD - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal Aardvark Therapeutics Inc|AARD - Gunggung utang perusahaan|Utang marang nilai buku Aardvark Therapeutics|AARD - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Aardvark Therapeutics|Rasio cepet aardvarktherapeutics.com
- informasi bathi lan kelipatan valuasi:
AARD - Penghasilan resik perusahaan
Analisis dhasar perusahaan:Aardvark Therapeutics
Barang utama Aardvark Pharma

The investment attractiveness of Aardvark Therapeutics Inc (AARD) is based on patent-protected developments in the field of metabolic diseases. The metric compares total liabilities to net assets, determining the degree of financial autonomy. An analysis of the debt-to-equity ratio allows for an assessment of stability amid high clinical trial costs. Low leverage minimizes bankruptcy risk within this R&D-intensive sector, confirming the fundamental strength of the business.

Analisis pesaing Aardvark Therapeutics Inc

Utang marang Ekuitas Ascendis Pharma|Madrigal Pharmaceuticals Inc - Utang Agregat marang Ekuitas|Total Utang marang Modal CORT|RYTM (Rhythm Corp) - Rasio Kabeh Utang marang Dana Pribadi|Total Utang marang Modal AKRO (Akero Therapeutics)|Total Utang marang Modal metsera.com MTSR|MLTX - Utang marang Ekuitas|Rasio Kabeh Utang marang Dana Pribadi CRNX (Crinetics Pharmaceuticals, Inc.)|NewAmsterdam Pharma N.V. (NAMS) - Utang marang Ekuitas|Rasio Total Utang marang Ekuitas Soleno Therapeutics Corp|FOLD (Amicus Therapeutics) - Total Utang marang Modal|Total Utang marang Modal 89bio.com|Rasio Total Utang marang Ekuitas AGIO (Agios Pharmaceuticals, Inc.)|GPCR (Structure Therapeutics Inc) - Rasio Kabeh Utang marang Dana Pribadi|Utang marang Ekuitas MiMedx Group MDXG|RZLT - Rasio Total Utang marang Ekuitas|Lexicon Pharmaceuticals - Total Utang marang Modal|Utang marang Modal mbxbio.com|ALT (Altimmune) - Rasio Total Utang marang Ekuitas|SGMT: Utang Agregat marang Modal|BIOA (BioAge Labs Inc.) - Total Utang marang Modal|Total Utang marang Modal Biomea Fusion Corp|Total Utang marang Modal QNCX|Utang marang Ekuitas GUTS (fractyl.com)|Utang marang Ekuitas vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Utang marang Modal|PLUR - Utang marang Ekuitas|SYBX: Utang marang Ekuitas|LPCN: Total Utang marang Modal|MTNB - Koefisien Total Utang marang Modal|Utang marang Ekuitas Spruce Biosciences, Inc.|Galecto Inc (GLTO) - Koefisien Total Utang marang Modal|Utang marang Ekuitas Carmell Corp (CTCX)|Rasio Total Utang marang Ekuitas Lumos Therapeutics LUMO|Total Utang marang Modal ONVO (Organovo Holdings, Inc.)|Total Utang marang Modal radiuspharm.com RDUS